Screener
GeneDx Holdings WGS Total Cost of Revenue
Total Cost of Revenue at other companies
Other financials
Where this comes from
Reported directly by GeneDx Holdings in its filing.
Tagged under the XBRL concept us-gaap:CostOfGoodsAndServicesSold.
The source filing: GeneDx Holdings’s 10-Q, filed May 4, 2026.
- Filed
- May 4, 2026, 4:15 PM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001818331-26-000041
| Line item | Three months ended March 31, 2026 | 2025 |
|---|---|---|
| Diagnostic test revenue | $101,299 | $85,759 |
| Other revenue | 955 | 1,356 |
| Total revenue | 102,254 | 87,115 |
| Cost of services | 34,043 | 28,639 |
| Gross profit | 68,211 | 58,476 |
| Research and development | 19,804 | 12,577 |
| Selling, general and administrative | 74,591 | 50,450 |
| Impairment loss | 31,287 | — |
Item 1. Condensed Consolidated Financial Statements (Unaudited)
FAQ
- What is GeneDx Holdings's total cost of revenue?
- GeneDx Holdings (WGS) reported total cost of revenue of $34.04M in Q1 2026.
- How has GeneDx Holdings's total cost of revenue changed year-over-year?
- GeneDx Holdings's total cost of revenue increased by 18.9% year-over-year, from $28.64M to $34.04M.
- What is the long-term trend for GeneDx Holdings's total cost of revenue?
- Over 4 years (2021 to 2025), GeneDx Holdings's total cost of revenue has grown at a -13.3% compound annual growth rate (CAGR), from $228.8M to $129.37M.
- What does total cost of revenue mean?
- The aggregate of all direct costs attributable to producing goods and delivering services that generated the company's revenue, including materials, labor, and overhead.
Ask your AI about GeneDx Holdings's total cost of revenue.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude